|
|
Idexx Laboratories Inc (IDXX) |
|
|
|
| |
IDXX's Net Income Growth by Quarter and Year
Idexx Laboratories Inc's Net Income results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| IDXX Net Income (in millions $) |
FY 2024 |
FY 2023 |
FY 2022 |
FY 2021 |
| IV Quarter |
December |
-
|
194.52
|
172.21
|
162.77
|
| III Quarter |
September |
-
|
212.23
|
180.94
|
175.18
|
| II Quarter |
June |
203.30
|
224.24
|
131.98
|
202.61
|
| I Quarter |
March |
235.58
|
214.05
|
193.97
|
204.29
|
| FY |
|
438.88
|
845.04
|
679.10
|
744.85
|
| IDXX Net Income second quarter 2024 Y/Y Growth Comment |
Idexx Laboratories Inc reported decrease in Net Income in the second quarter 2024 by -9.34% to $ 203.30 millions, from the same quarter in 2023.
The decrease in the second quarter 2024 Idexx Laboratories Inc's Net Income compares unfavorably to the Company's average Net Income increase of 13.87%.
According to the results reported in the second quarter 2024, Idexx Laboratories Inc achieved the best Net Income growth in In Vitro & In Vivo Diagnostic Substances industry. While Idexx Laboratories Inc' s Net Income decline of -9.34% ranks overall at the positon no. 417 in the second quarter 2024.
|
| IDXX Net Income ( Y/Y Growth %) |
2024
|
2023 |
2022 |
2021 |
| IV Quarter |
December |
- |
12.96 % |
5.8 % |
-6.97 % |
| III Quarter |
September |
- |
17.29 % |
3.29 % |
19.72 % |
| II Quarter |
June |
-9.34 % |
69.9 % |
-34.86 % |
35.98 % |
| I Quarter |
March |
10.06 % |
10.35 % |
-5.05 % |
82.63 % |
| FY |
|
- |
24.44 % |
-8.83 % |
27.95 % |
IDXX Net Income (Quarter on Quarter Growth %) |
2024
|
2023 |
2022 |
2021 |
| IV Quarter |
December |
- |
-8.34 % |
-4.82 % |
-7.08 % |
| III Quarter |
September |
- |
-5.36 % |
37.1 % |
-13.54 % |
| II Quarter |
June |
-13.7 % |
4.76 % |
-31.96 % |
-0.82 % |
| I Quarter |
March |
21.11 % |
24.3 % |
19.17 % |
16.76 % |
| FY (Year on Year) |
|
- |
24.44 % |
-8.83 % |
27.95 % |
| Net Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 58.22 % |
13.87 % |
-12.82 % |
| (Jun 30 2021) |
|
(Sep. 30, 2015) |
|
|
| Net Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 58.22 % |
13.87 % |
-12.82 % |
| (Jun 30 2021) |
|
(Sep. 30, 2015) |
|
| Net Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024 |
Idexx Laboratories Inc's Q/Q Net Income Growth
| Net Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 133.68 % |
7.12 % |
-50.25 % |
| (Mar 31 2018) |
|
|
| IDXX's II. Quarter Q/Q Net Income Comment |
In the II. Quarter 2024 Idexx Laboratories Inc reported drop in Net Income sequentially by -13.7% to $ 203.30 millions, from $ 235.58 millions declared a quarter before.
Albeit seasonal circumstance usually fuel II. Quarter 2024 performance, this simply was not enough to rescue In Vitro & In Vivo Diagnostic Substances's company outcome, María Ángeles Molina, an industry expert pointed out and mentioned that average sequential Net Income growth is at 7.12% for IDXX.
Within In Vitro & In Vivo Diagnostic Substances industry Idexx Laboratories Inc achieved highest sequential Net Income growth. While Idexx Laboratories Inc's Net Income growth quarter on quarter, overall rank is 838. |
|
|
|
| Net Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 133.68 % |
7.12 % |
-50.25 % |
| (Mar 31 2018) |
|
|
| IDXX's II. Quarter Q/Q Net Income Comment |
In the II. Quarter 2024 Idexx Laboratories Inc realized drop in Net Income sequentially by -13.7% to $ 203.30 millions, from $ 235.58 millions declared in the previous quarter.
Although periodic circumstance normally elevate II. Quarter 2024 Net Income, it simply has not been sufficient to recover In Vitro & In Vivo Diagnostic Substances's company II. Quarter outcome, María Ángeles Molina, an industry expert pointed out.
Within In Vitro & In Vivo Diagnostic Substances industry Idexx Laboratories Inc achieved highest sequential Net Income growth. While Idexx Laboratories Inc's Net Income growth quarter on quarter, overall rank is 838. |
|
Idexx Laboratories Inc's 12 Months Net Income Growth Year on Year
Net Income TTM Growth |
12 Months Ending
(Jun 30 2024) |
12 Months Ending
(Mar 31 2024) |
12 Months Ending
(Dec 31 2023) |
12 Months Ending
(Sep 30 2023) |
12 Months Ending
(Jun 30 2023) |
| Cumulative Net Income 12 Months Ending |
$ 845.63 |
$ 866.57 |
$ 845.04 |
$ 822.73 |
$ 791.44 |
| Y / Y Net Income Growth (TTM) |
6.85 % |
23.94 % |
24.44 % |
22.86 % |
19.21 % |
| Year on Year Net Income Growth Overall
Ranking |
# 358 |
# 458 |
# 819 |
# 920 |
# 329 |
| Seqeuential Net Income Change (TTM) |
-2.42 % |
2.55 % |
2.71 % |
3.95 % |
13.2 % |
| Seq. Net Income Growth (TTM) Overall
Ranking |
# 417 |
# 402 |
# 683 |
# 727 |
# 332 |
| Cumulative Net Income growth
Comment |
With the quarterly Net Income reported in the Jun 30 2024 period, Idexx Laboratories Inc's cumulative twelve months Net Income were $ 846 millions, company would post below average annual Net Income growth of 13.2% year on year, if the fiscal year would end at Jun 30 2024.
A slow-down in the Idexx Laboratories Inc's Net Income growth from the 235.58% growth in Mar 31 2024. Despite that, Idexx Laboratories Inc showed the highest Net Income growth, among it's peers in In Vitro & In Vivo Diagnostic Substances industry.
Within the Healthcare sector 33 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 358, from total ranking in previous quarter at 458. |
| Net Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
58.22 % |
13.87 % |
-12.82 % |
|
|
|
|
|
| Net Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
58.22 % |
13.87 % |
-12.82 % |
|
|
|
| Net Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 1 |
| Sector |
# 35 |
| S&P 500 |
# 417 |
|
| Cumulative Net Income growth
Comment |
With the quarterly Net Income reported in the Jun 30 2024 period, Idexx Laboratories Inc's cumulative twelve months Net Income were $ 846 millions, company would post below average annual Net Income growth of -12.82% year on year, if the fiscal year would end at Jun 30 2024.
A slow-down in the Idexx Laboratories Inc's Net Income growth from the 235.58% growth in Mar 31 2024. Despite that, Idexx Laboratories Inc showed the highest Net Income growth, among it's peers in In Vitro & In Vivo Diagnostic Substances industry.
Within the Healthcare sector 33 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 358, from total ranking in previous quarter at 458. |
| Net Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
58.22 % |
13.87 % |
-12.82 % |
|
|
|
| Net Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
58.22 % |
13.87 % |
-12.82 % |
|
|
|
| Net Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 1 |
| Sector |
# 35 |
| S&P 500 |
# 417 |
|
